ÂÜÀòÂÒÂ×

Paul Guptill has extensive work experience in the biopharmaceutical industry. Paul currently holds the position of Vice President CMC Biologics at Avalo Therapeutics since May 2022. Prior to this role, they served as the Executive Director, Product Supply at Avalo Therapeutics from September 2021 to May 2022. Before joining Avalo Therapeutics, Paul worked at Bristol Myers Squibb as a Senior Director CAT T Strategic Product Lead from July 2020 to September 2021. Paul also had a significant tenure at Celgene as a Senior Director Technical Commercialization Team Lead from March 2017 to July 2020. Paul has a history with Bristol-Myers Squibb, having served as a Strategic Product Leader from June 2014 to March 2017. Paul also held the position of Director, New Products Management at Bristol-Myers Squibb, Inc. from an unknown start date until November 2014. Prior to their time at Bristol-Myers Squibb, Paul worked at Medarex as a Senior Director Manufacturing Services from May 1999 to April 2010. Paul began their career at Stryker Biotech as a Supervisor Downstream Manufacturing from August 1996 to May 1999, and prior to that, they were a Process Development Scientist at Merck Serono from June 1992 to August 1996. Throughout their career, Paul has gained expertise in various aspects of biopharmaceutical manufacturing, technical commercialization, product supply, and new product management.

Paul Guptill attended Messiah University from 1983 to 1987, where they earned a Bachelor of Science degree in Chemistry and Biology. Following their undergraduate studies, they pursued further education at the University of New Hampshire from 1989 to 1992. During this time, they obtained a Master's degree in Chemistry.